Brief: Verve Therapeutics Announces Verve-101 Awarded Innovation Passport By The Uk Mhra For The Treatment Of Heterozygous Familial Hypercholesterolemia
14/02/2023 11:34
Feb 14 (Reuters) - Verve Therapeutics Inc VERV.O :
* VERVE THERAPEUTICS ANNOUNCES VERVE-101 AWARDED INNOVATION
PASSPORT BY THE UK MHRA FOR THE TREATMENT OF HETEROZYGOUS
FAMILIAL HYPERCHOLESTEROLEMIA
* VERVE THERAPEUTICS INC - EXPECTS TO REPORT INITIAL
CLINICAL
DATA FROM DOSE ESCALATION PORTION OF HEART-1 CLINICAL TRIAL IN
SECOND HALF OF 2023
* VERVE THERAPEUTICS INC - VERVE EXPECTS TO REPORT INITIAL
CLINICAL DATA FROM DOSE ESCALATION PORTION OF HEART-1 CLINICAL
TRIAL IN SECOND HALF OF 2023
Source text for Eikon: ID:nGNX2Pxvp5
Further company coverage: VERV.O
((Reuters.Briefs@thomsonreuters.com;;))